Millennium Management’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
Other funds holding ABCL
BBA
Millennium Management's ABCL Position: Q3 2026 in Review
Millennium Management increased its AbCellera Biologics (ABCL) stake by 293% in Q3 2026, buying an estimated $14.4M and bringing the position to 2,038,187 shares worth $29.7M. The position accounts for 0.01% of the portfolio, ranked #1301.
Millennium Management first reported a position in ABCL in Q4 2020 and has held it in 24 quarters since. The position peaked at $31.5M in Q2 2022. 164 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.
- Millennium Management held 2,038,187 shares of AbCellera Biologics worth $29.7M as of Q3 2026.
- Millennium Management bought 1,519,616 AbCellera Biologics shares in Q3 2026, an estimated $14.4M.
- AbCellera Biologics made up 0.01% of Millennium Management's portfolio in Q3 2026, its #1301 holding.
- Millennium Management first reported a position in AbCellera Biologics in Q4 2020 and has held it in 24 quarters since.
- Millennium Management's AbCellera Biologics position peaked at $31.5M in Q2 2022.
- 164 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.
Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.